Printer Friendly

BELMAC ANNOUNCES RESULTS OF CLINICAL STUDIES

 BELMAC ANNOUNCES RESULTS OF CLINICAL STUDIES
 TAMPA, Fla., June 30 /PRNewswire/ -- Belmac Corporation (AMEX: BLM)


announced today the completion of two clinical studies comparing its new macrolide antibiotic, Biolid(TM), to Rulid, another new generation macrolide, and Cefodox, a third generation oral cefalosporin.
 The results of these studies demonstrate that Biolid(TM) is as effective and as well tolerated as both Rulid and Cefodox in the treatment of streptococcus pharyngitis. These results are significant in that they position Biolid(TM) as a first line therapy for treatment of respiratory tract infections, particularly given Biolid's(TM) established record of clinical safety.
 The two double blind double placebo controlled studies were conducted in France and involved a total of 309 patients. Patients on Biolid(TM) received two 500 mg doses per day for a period of 10 days.
 Biolid(TM), a new patented highly absorbed derivative of erythromycin, has been approved for marketing in France where Belmac began marketing the product on March 17 of this year. The company, using its own sales force, achieved a 4.2 percent penetration (measured in units) of the French market for macrolide antibiotics in the first 60 days of marketing.
 Belmac recently filed for registration of Biolid(TM) in Spain and in Mexico. Earlier this year, Belmac filed an IND with the United States FDA for testing Biolid in its twice-a-day dosage form in the United States.
 Belmac Corporation is an emerging pharmaceutical company with a focus on anti-infective drugs.
 -0- 6/30/92
 /CONTACT: Russel Ketchum, vice president-corporate communications of Belmac Corporation, 813-286-4401 or 800-877-6533/
 (BLM) CO: Belmac Corporation ST: Florida IN: MTC SU:


SS-AW -- FL006 -- 5223 06/30/92 13:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:279
Previous Article:EQUIFAX AND EIGHTEEN STATES SIGN AGREEMENT OF ASSURANCES
Next Article:CALIFORNIA UNITED BANK ENTERS INTO FORMAL AGREEMENT WITH THE OFFICE OF THE COMPTROLLER OF THE CURRENCY
Topics:


Related Articles
BELMAC FILES IND WITH FDA FOR BIOLID(TM); PHASE III CLINICAL TRIAL TO BEGIN IN FEBRUARY 1992
BELMAC COMPLETES $11.6 MILLION PRIVATE OFFERING
BELMAC ADDS TWO TOP PHARMACEUTICAL EXECUTIVES; FORMER SMITHKLINE BEECHAM, BRISTOL MYERS SQUIBB SENIOR VPs TO COMPLETE MANAGEMENT TEAM
BELMAC ISSUES UPDATE ON RESEARCH AND DEVELOPMENT ACTIVITIES
BELMAC COMPLETES CLINICAL STUDY ON BIOLID(R); LAUNCHES BELMACINA(R) IN SPAIN
BELMAC CORPORATION TO ACQUIRE ITALIAN PHARMACEUTICAL COMPANY
BELMAC COMPLETES PHASE I CLINICAL TESTING ON TRANSDERMAL PATCH CO-DEVELOPED WITH ALZA CORPORATION
BELMAC GRANTED UNITED STATES PATENT FOR ANTI-MALARIAL DRUGS
BELMAC SUCCESSFULLY COMPLETES BIOLID(R) TWICE-A-DAY TABLET STUDY
BELMAC'S BIOLID(R) APPROVED IN SPAIN

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters